Pharvaris (NASDAQ:PHVS) Sees Large Decrease in Short Interest

Pharvaris (NASDAQ:PHVS - Get Free Report) saw a large drop in short interest in December. As of December 15th, there was short interest totalling 152,100 shares, a drop of 24.8% from the November 30th total of 202,200 shares. Based on an average daily trading volume, of 85,200 shares, the short-interest ratio is presently 1.8 days. Approximately 0.9% of the shares of the stock are short sold.

Analysts Set New Price Targets

Separately, Oppenheimer upped their target price on Pharvaris from $38.00 to $42.00 and gave the stock an "outperform" rating in a research note on Friday, September 6th.

Hedge Funds Weigh In On Pharvaris

Institutional investors and hedge funds have recently bought and sold shares of the stock. Public Employees Retirement System of Ohio bought a new stake in Pharvaris in the third quarter valued at approximately $57,000. Barclays PLC purchased a new position in shares of Pharvaris in the third quarter worth $106,000. HighVista Strategies LLC raised its holdings in Pharvaris by 35.9% during the 3rd quarter. HighVista Strategies LLC now owns 22,768 shares of the company's stock valued at $422,000 after buying an additional 6,018 shares during the last quarter. Jane Street Group LLC purchased a new stake in Pharvaris during the 3rd quarter valued at $526,000. Finally, Geode Capital Management LLC grew its holdings in Pharvaris by 18.4% in the 3rd quarter. Geode Capital Management LLC now owns 36,977 shares of the company's stock worth $685,000 after acquiring an additional 5,753 shares during the last quarter.

Pharvaris Trading Down 0.4 %

Shares of NASDAQ:PHVS traded down $0.07 on Friday, reaching $19.43. 20,111 shares of the company traded hands, compared to its average volume of 87,925. The stock has a market capitalization of $618.65 million, a P/E ratio of -6.94 and a beta of -3.17. The business's 50-day simple moving average is $21.02 and its 200 day simple moving average is $19.35. Pharvaris has a 52 week low of $15.37 and a 52 week high of $33.00.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.